<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03722147</url>
  </required_header>
  <id_info>
    <org_study_id>AK105-201</org_study_id>
    <nct_id>NCT03722147</nct_id>
  </id_info>
  <brief_title>A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma</brief_title>
  <official_title>A Single-arm, Multicenter, Open-label, Phase I/II Study of AK105 as Monotherapy in Relapsed or Refractory Classic Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, multicenter, phase I/II study to evaluate efficacy and
      safety of AK105 in patients with relapsed or refractory classic Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) assessed by Independent Radiology Review Committee (IRRC) per the Lugano 2014 Classification</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>ORR defined as the proportion of subjects who achieves a best overall response of CR or PR, assessed by IRRC per the Lugano 2014 Classification.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events (AEs)</measure>
    <time_frame>From the time of informed consent signed through 90 days after the last dose of AK105</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR assessed by Investigator</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>ORR defined as the proportion of subjects who achieves a best overall response of CR or PR, assessed by Investigator per the Lugano 2014 Classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>From the date that CR or PR are first occurred to the date of objective disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>From the first dose of AK105 to the date of the date of objective disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DCR defined as the proportion of subjects response of CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for â‰¥8 weeks) per the Lugano 2014 Classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed concentration (Cmin) of AK105 at steady state</measure>
    <time_frame>From first dose of AK105 through 30 days after last dose of AK105</time_frame>
    <description>The endpoints for assessment of PK of AK105 include serum concentrations of AK105 at different timepoints after AK105 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From first dose of AK105 through to 90 days after last dose of AK105</time_frame>
    <description>The immunogenicity of AK105 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>AK105</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK105 200 mg intravenously (IV) every-2-weeks (Q2W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AK105</intervention_name>
    <description>AK105 200 mg intravenously (IV) every-2-weeks (Q2W)</description>
    <arm_group_label>AK105</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written and signed informed consent

          2. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1

          3. Histologically confirmed classic Hodgkin's lymphoma (cHL) (based on tumor tissue
             obtained within 3 years prior to enrollment).

          4. Relapsed (disease progression during or after most recent therapy) or refractory
             (failure to achieve CR or PR after most recent therapy) cHL and meet any of the
             following criterions:

               1. Recurrence or disease progression after autologous hematopoietic stem cell
                  transplantation.

               2. For subject without receiving , the subject has received at least 2 lines of
                  prior systemic chemotherapy. Refractory subject is defined as subject who has not
                  achieved PR after at least 2 cycles of treatment, or subject who has not achieved
                  CR after at least 4 cycles of treatment. If the best response to treatment is PD
                  or the reason for ending the treatment is PD, the subject is consider as
                  refractory without requirement on the number of cycles of treatment that the
                  subject has received. For relapsed subjects, disease progression occurred for the
                  subject who has received at least 2 line of prior systemic chemotherapy.

          5. Subject must have at least one measurable lesion (&gt; 1.5 cm in the longest diameter, or
             &gt; 1 cm in the longest diameter with uptake on 18FDG-PET)according to the Lugano 2014
             criteria.

          6. Adequate organ functions.

          7. Use effective methods of contraception.

        Exclusion Criteria:

          1. Known nodular lymphoma predominant Hodgkin lymphoma or Grey zone lymphoma.

          2. Lymphoma involving the central nervous system.

          3. Participated in other clinical studies of experimental drugs or received research
             treatment or used experimental equipment within 4 weeks prior to the first dose of
             AK105.

          4. Concurrent enrollment in another clinical study, unless it is an observational
             (non-interventional) clinical study or the follow-up period of an interventional
             study.

          5. Receipt of the last radiotherapy or the last dose of anticancer therapy (chemotherapy,
             target therapy, immunotherapy or tumor embolism, etc.) with 4 weeks prior to the first
             dose of AK105. Receipt of the last dose of nitrocarbamide or mitomycin C within 6
             weeks prior to the first dose of AK105.

          6. Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTL4 antibody or any other antibody
             or drug targeting T-cell costimulation or checkpoint pathways such as ICOS, or
             agonists such as CD40, CD137, GITR, OX40 etc..

          7. Had other active malignancies within 5 years prior to enrollment. Locally curable
             cancer (manifested as cured) is excluded, such as basal or cutaneous squamous cell
             carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ.

          8. Active, known or suspected autoimmune diseases, or a history of the disease within the
             past 2 years, except the following: vitiligo, alopecia, Graves' disease, psoriasis or
             eczema that do not require systemic treatment within the last 2 years, hypothyroidism
             (caused by autoimmune thyroiditis) only requiring a stable dose of hormone replacement
             therapy, type I diabetes requiring only a stable dose of insulin replacement therapy,
             or diseases not expected to recur in the absence of external triggering factors.

          9. Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative
             colitis or chronic diarrhea).

         10. Subjects with a condition requiring systemic treatment with either corticosteroid (&gt;
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14
             days of study drug administration.

         11. History of testing positive for human immunodeficiency virus (HIV) or known acquired
             immunodeficiency syndrome (AIDS).

         12. History of primary immunodeficiency.

         13. History of active tuberculosis.

         14. History of allogeneic stem cell transplantation or organ transplantation.

         15. Autologous hematopoietic stem cell transplantation performed within 90 days prior to
             the first dose of AK105.

         16. History of gastrointestinal perforation and /or within 6 months prior to enrollment.

         17. History of interstitial lung disease.

         18. Patients with untreated chronic hepatitis B or with HBV DNA exceeding 500 IU/mL, or
             with active hepatitis C should be excluded. Inactive HBsAg carriers, treated and
             stable hepatitis B patients (HBV DNA &lt; 500 IU/mL), or cured hepatitis C patients can
             be enrolled. For patients with positive HCV antibody, they are eligible to participate
             in the study only if the test result of HCV RNA is negative.

         19. Major surgical procedure (as defined by the investigator) within 30 days prior to the
             first dose of AK105 or still recovering from prior surgery. Local procedures (eg,
             placement of a systemic port, core needle biopsy, and prostate biopsy) are allowed if
             completed at least 24 hours prior to the administration of the first dose of study
             treatment.

         20. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated
             drainage.

         21. Active infections requiring systemic treatment.

         22. Uncontrolled concurrent disease, including but not limited to, persistent or active
             infection, symptomatic congestive heart failure (according to the New York heart
             association functional class defined 3 or 4), out of control of high blood pressure,
             unstable angina, arrhythmia, severe peptic ulcer or gastritis, activity, or mental
             illness/social status which will limit the participants compliance requirements or
             damage to the participants to provide written informed consent.

         23. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to
             National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events
             (CTCAE) (NCI CTCAE v4.03) Grade 0 or 1, or to levels dictated in the
             inclusion/exclusion criteria with the exception of alopecia. Subjects with
             irreversible toxicity that is not reasonably expected to be exacerbated by the study
             drug may be included (eg, hearing loss) after consultation with the medical monitor.
             Subjects with â‰¤ Grade 2 neuropathy will be evaluated on a case-by-case basis after
             consultation with the medical monitor.

         24. Receipt of live or attenuated vaccination within 30 days prior to the first dose of
             AK105, or plan to have live or attenuated vaccination during the study.

         25. Known allergy or reaction to any component of the AK105 formulation.

         26. History of severe allergic reaction to any other monoclonal antibodies.

         27. Women who are pregnant or nursing.

         28. Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the investigational product or interpretation of subject safety or study
             results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoping Jin</last_name>
    <phone>+86 (0760) 8987 3999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beiing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Zhang</last_name>
      <phone>13810378747</phone>
      <email>55245751@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jun Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuqin Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>October 26, 2018</last_update_submitted>
  <last_update_submitted_qc>October 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>immuno-oncology</keyword>
  <keyword>Classic Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

